Blends · Dosing reference

CJC-1295 (no DAC) + GHRP-6 Blend dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: Not established
Evidence grade: Not yet assessed
Vial sizes on the market: 10 mg
Other forms seen: —

What CJC-1295 (no DAC) + GHRP-6 Blend is

A combination of a GHRH analog lacking a drug affinity complex with the ghrelin-receptor agonist GHRP-6, studied in growth hormone axis signaling.

No mechanistic study of these two peptides administered together was identified, so no combined mechanism is described here ^6. The components are summarised separately below and each has its own page. Components CJC-1295 (no DAC) ( /library/cjc-1295-no-dac ) is a modified GRF(1-29) peptide; the published CJC-1295 pharmacology concerns albumin-binding bioconjugates whose long duration of action depends on the drug… How it works →

Key evidence

Teichman et al., J Clin Endocrinol Metab · 2006 · Humans (healthy adults)
The DAC form of CJC-1295, which is not the component named on this page, was associated with dose-dependent increases in plasma growth hormone and IGF-1 and a multi-day estimated half-life. ¹
Cibrian et al., Clin Sci (Lond) · 2006 · Rats (hepatic ischaemia/reperfusion) and cell lines
GHRP-6 given alone was associated with reduced markers of liver and intestinal injury and with increased cell migration in culture; no GHRH analog was co-administered. ²
Dominikowski et al., Front Endocrinol (Lausanne) · 2026 · Literature (GH-IGF-1 axis peptides marketed as research compounds)
Placed CJC-1295 with and without DAC and GHRP-6 among unregulated compounds, with tiers ranging from randomised trial data to a complete absence of human studies, and reported endocrine, metabolic, fluid-retention and injection-site adverse effects for the class. ³

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered CJC-1295 (no DAC) + GHRP-6 Blend. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for CJC-1295 (no DAC) + GHRP-6 Blend.

Cycle-length evidence for CJC-1295 (no DAC) + GHRP-6 Blend

CJC-1295 (no DAC) + GHRP-6 Blend draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

General research-context handling only, and there is an added consideration for a multi-component vial: the two components are separate molecules with separate stability and solubility behaviour, and no published stability data for them combined in one container were identified. Defer to the supplier's own stability and handling documentation for the specific lot. No preparation or administration instructions are given on this page.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Neither component is FDA-approved, and no approved product combining them exists ^3,4. A 2026 narrative review groups CJC-1295 with and without DAC, and GHRP-6, among unregulated compounds marketed as "research compounds" with no regulatory approval for physique or performance indications ^3. GHRP-6 appears in category 3 of FDA's May 14, 2026 503A bulk drug substances list, the category for substances nominated without adequate support; CJC-1295 does not appear on that list at all ^5.
United States (FDA): No FDA-approved application exists for either component or for the combination, and a DailyMed name search for CJC-1295 returned no drug label ^3,4. On FDA's May 14, 2026 503A bulk drug substances list, GHRP-6 is placed in category 3, Bulk Drug Substances Nominated Without Adequate Support, alongside GHRP-2; CJC-1295 does not appear in any of the three categories ^5. A 2026 review notes that gonadorelin was FDA-approved but is no longer manufactured, which is a separate matter from these peptides ^4.
Sport (WADA): Section S2.2.4 of the WADA 2026 Prohibited List, Growth Hormone Releasing Factors, names CJC-1295 among GHRH and its analogues and names GHRP-6 among GH-releasing peptides; the section's examples are introduced with "including, but not limited to" and the class is prohibited at all times ^7. The list names CJC-1295 without distinguishing DAC and no-DAC forms ^7. Because the wording is open-ended, the absence of a particular trade name from the list is not permission ^7. Detection methods for both substances in plasma have been published ^8.

Status varies by country and changes over time. How we describe regulatory status.

CJC-1295 (no DAC) + GHRP-6 Blend compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
CJC-1295 (no DAC) + GHRP-6 Blend	Not approved — research use only	—	None established	—
CJC-1295 (no DAC)	Not approved — research use only	C	None established	No half-life data specific to the no-DAC
GHRP-6	Not approved — research use only	B	None established	—
BPC-157 + TB-500 Blend	Not approved — research use only	C	None established	—
CJC-1295 (no DAC) + Ipamorelin Blend	Not approved — research use only	—	None established	—
Selank + Semax Blend	Not approved — research use only	—	None established	—

Frequently asked questions

What doses of CJC-1295 (no DAC) + GHRP-6 Blend have been studied in humans?

None that establish an amount. CJC-1295 (no DAC) + GHRP-6 Blend is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established CJC-1295 (no DAC) + GHRP-6 Blend cycle length?

No. We found no human studies that report treatment duration for CJC-1295 (no DAC) + GHRP-6 Blend.

How much bacteriostatic water should be added to a CJC-1295 (no DAC) + GHRP-6 Blend vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

Is CJC-1295 (no DAC) + GHRP-6 Blend FDA-approved?

Not approved — research use only. Neither component is FDA-approved, and no approved product combining them exists ^3,4. A 2026 narrative review groups CJC-1295 with and without DAC, and GHRP-6, among unregulated compounds marketed as "research compounds" with no regulatory approval for physique or performance indications ^3. GHRP-6 appears in category 3 of FDA's May 14, 2026 503A bulk drug substances list, the category for substances nominated without adequate support; CJC-1295 does not appear on that list at all ^5.

References

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab. 2006
Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure Clin Sci (Lond). 2006
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Front Endocrinol (Lausanne). 2026
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review Sex Med Rev. 2026
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
PubMed search: "CJC-1295" AND "GHRP-6" (3 records, none an experiment on the combination; searched 22 October 2026) PubMed. 2026
World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry Anal Bioanal Chem. 2013
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs Mo Med. 2026

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error